Janet Hampton Explains the Distress Thermometer Study

The fast track status from the FDA is supported by findings from a phase 1 trial in glioblastoma, which demonstrated the overall survival benefit from DOC1021.

Holly Chitwood, DNP, FNP-C, AGACNP-BC, explains how circulating tumor DNA monitoring helps providers screen minimal residual disease in individuals with colorectal cancer.

Disease-free survival and overall survival improved with celecoxib plus advanced chemotherapy in patients with PIK3CA-mutated stage III colon cancer.

In this episode of "The Vitals," Terri Pollack, DNP, APRN, FNP-C, PMHNP-BC, underscores potentially practice-changing data which were presented during the 2023 GI Cancers Symposium.

Perioperative chemotherapy with FLOT improved overall survival in patients with resectable esophageal cancer compared with neoadjuvant chemoradiation with CROSS.

Six-year administration of imatinib maintenance therapy—compared with the standard 3 years—improved disease-free survival in gastrointestinal stromal tumors.